Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
A Daiichi Sankyo quarterly report that should have celebrated strong commercial execution was instead derailed by an accounting error and manufacturing losses. | A Daiichi Sankyo quarterly report that should have celebrated strong commercial execution was instead derailed by an accounting error and manufacturing losses.
Daiichi scopre 29B yen non contabilizzati in SG&A; revenue +21% ma core profit +6%, azioni -11%. Manufacturing losses ADC (AstraZeneca) + zero profit translation da revenue growth rivelano margini erosi e governance risk.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

Takeda's first-in-class orexin treatment won an FDA nod in narcolepsy. Daiichi Sankyo faced investor pushback after admitting to…

A recent antitrust verdict has prompted Takeda to revise its 2025 financials, putting the drugmaker at a 152 billion Japanese yen…

Daiichi revealed on Friday it expects to post an “extraordinary” loss of 149.4 billion Japanese yen, or around $950 million. It…

As Teva proceeds down the more muted growth path that it telegraphed early this year, the generics and innovative medicines…

Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. |…

Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese…